26 Apr 23
tranScrip, the fast-growing contract drug development organisation supporting the entire lifecycle of medicines and medical devices, has completed full integration of Real Regulatory, a leading regulatory affairs company it acquired in March 2022.
The full integration of both companies further strengthens tranScrip’s position as the life science powerhouse, providing strategic expertise and operational delivery across all phases of drug development, from preclinical to registration and post-marketing.
Both companies, now operating as one powerful team, will continue on its journey, building a leading, science-driven organisation with one objective in mind, to provide pharma and biotech companies with drug development expertise and deliver new medicines to patients.
Dr Marcin Mankowski, the CEO of tranScrip said: “After a year of Real Regulatory operating as tranScrip’s subsidiary, we are excited to have completed full integration of our companies. It puts us in a better position to continue tranScrip’s growth, aimed at strengthening our multi-functional drug development teams of pharmaceutical physicians, regulatory experts and scientists across all phases of product lifecycle and different therapy areas.”
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.
